Evidence map›Paper›PMID 35402715›Full record

ArticleClinical and experimental hepatology2021

Chemokine receptor CXCR6 gene polymorphism and treatment response of chronic hepatitis C virus in Egyptian patients.

Mona M Hassona, Tamer Fouad, Merhan Osama Helmi, Heba Samy Mohammed Ghanem, Heba E Abd Elrhman, Eman Abdelsameea

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mona M HassonaClinical Pathology, National Liver Institute, Menoufia University, Egypt.
Tamer FouadHepatology and Gastroenterology, National Liver Institute, Menoufia University, Egypt.
Merhan Osama HelmiClinical Pathology, National Liver Institute, Menoufia University, Egypt.
Heba Samy Mohammed GhanemClinical Pathology, National Liver Institute, Menoufia University, Egypt.
Heba E Abd ElrhmanClinical Pathology, Faculty of Medicine, Zagazig University, Egypt.
Eman AbdelsameeaNational Liver Institute, Egypt.
Menoufia University · EGZagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim of the study: Despite achieving a high cure rate of chronic hepatitis C nowadays, treatment failure remains a major concern and host genetic polymorphism could have a possible relation. The aim was to evaluate the role of chemokine receptor CXCR6 gene polymorphism in treatment response to direct acting antivirals (DAAs) in chronic hepatitis C virus (HCV) patients. Material and methods: We investigated the chemokine receptor CXCR6 gene single nucleotide polymorphism rs2234358 in three groups. Responder and non-responder groups (each comprising 50 naïve patients) and a control group of 50 apparently healthy individuals were studied. Results: Genotype distribution revealed a significant difference ( Conclusions: CXCR6 gene (rs2234358) polymorphism could have a potential role in the virological treatment response with a protective effect of the T allele. This could explain the higher treatment success rate of Egyptian HCV patients.

Indexed as

CXCR6direct-acting antivirals (DAAs)hepatitis C virus (HCV)polymorphismsustained virological response

Identifiers

PMID35402715
PMCPMC8977876
OpenAlexW4206172372

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.